Skip to main content
. 2010 Jun 16;92(3):660–667. doi: 10.3945/ajcn.2010.29350

TABLE 2.

Characteristics of subjects with cystic fibrosis and pancreatic insufficiency by vitamin K status presented as plasma PIVKA-II (proteins induced by vitamin K absence–factor II)1

PIVKA-II group
All (n = 60) Sufficient: ≤2.0 μg/L (n = 30) Deficient: >2.0 μg/L (n = 30)
Age (y) 15.4 ± 4.32 15.3 ± 4.0 15.5 ± 4.6
Female sex (%) 43 47 40
DF508 homozygous (%) 53 53 53
Height z score −0.3 ± 0.9 −0.3 ± 1.0 −0.3 ± 0.9
Weight z score −0.4 ± 0.9 −0.7 ± 0.9 −0.2 ± 0.8a
BMI z score −0.4 ± 0.8 −0.6 ± 0.8 −0.1 ± 0.8a
LBM (kg) 39.8 ± 13.0 38.0 ± 11.9 41.6 ± 14.1
FM (kg) 9.8 ± 5.7 9.1 ± 3.8 10.4 ± 7.1
Fat (%) 19.3 ± 6.4 19.4 ± 5.7 19.3 ± 7.1
FEV1 (% of predicted) 80 ± 19 75 ± 18 86 ± 18a
Vitamin K status
n 60 30 30
 Osteocalcin (ng/mL) 21 (3, 85)3 21 (4, 37) 22 (3, 85)
 ucOC (%) 33 (4, 66) 21 (4, 61) 46 (12, 66)
 <20% 30 50 10
 20–50% 50 43 57
 >50% 20 7 33a
 PIVKA-II (μg/L) 2 (0, 42) 2 (0, 2) 5 (2, 42)
Supplement intake4
n 60 30 30
 Vitamin K (μg/d) 300 (0, 10,000) 864 (0, 10,000) 163 (0, 5300)
Dietary intake
n 45 21 24
 Energy (kcal) 2913 (1531, 5293) 2965 (1531, 5098) 2863 (1618, 5293)
 EER, active (%) 112 (65, 202) 124 (65, 202) 108 (73, 178)
 Fat (% of energy) 33 (23, 44) 33 (23, 42) 32 (23, 44)
 Vitamin K (μg/d) 67 (22, 780) 74 (27, 780) 61 (22, 410)
 Vitamin K (% of AI) 98 (26, 866) 105 (37, 866) 78 (26, 524)
Serum chemistry
n 60 30 30
 25(OH)D (ng/mL) 22 (6, 35) 23 (12, 35) 20 (6, 34)
1

LBM, lean body mass; FM, fat mass; FEV1, forced expiratory volume in 1 s; ucOC, undercarboxylated osteocalcin; EER, estimated energy requirement; AI, Adequate Intake; 25(OH)D, serum 25-hydroxyvitamin D. Significant differences were assessed by using a Student's t test or Wilcoxon's rank-sum test: aP < 0.05, deficient compared with sufficient.

2

Mean ± SD (all such values).

3

Median; range in parentheses (all such values).

4

On the basis of reported vitamin K supplement intake.

HHS Vulnerability Disclosure